Search research articles
Contact Us
Filters
Showing results (421-430 of 478) with videos related to
Page
of 48
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN
|
March 10, 2012
Eculizumab for dense deposit disease and C3 glomerulonephritis
Andrew S Bomback, Richard J Smith, Gaetano R Barile, et al.
The Journal of Clinical Investigation
|
December 5, 2002
NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele
Hiroyasu Tsukaguchi, Akulapalli Sudhakar, Tu Cam Le, et al.
Applied and Environmental Microbiology
|
December 22, 2009
High heterogeneity within methicillin-resistant Staphylococcus aureus ST398 isolates, defined by Cfr9I macrorestriction-pulsed-field gel electrophoresis profiles and spa and SCCmec types
M A Argudín, A Fetsch, B-A Tenhagen, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
July 26, 2011
Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy
Roberta Camilla, Hitoshi Suzuki, Valentina Daprà, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
July 20, 2023
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
Sean J Barbour, Fernando C Fervenza, Dilshani Induruwage, et al.
Kidney International
|
January 10, 2018
C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy
Andrew S Bomback, Dominick Santoriello, Rupali S Avasare, et al.
American Journal of Nephrology
|
December 20, 2003
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy
W Kline Bolton, Daniel C Cattran, Mark E Williams, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 14, 2018
<i>UBD</i> modifies <i>APOL1</i>-induced kidney disease risk
Jia-Yue Zhang, Minxian Wang, Lei Tian, et al.
BMC Nephrology
|
October 1, 2008
NPHS2 variation in focal and segmental glomerulosclerosis
Stephen J Tonna, Alexander Needham, Krishna Polu, et al.
Journal of Diabetes and Its Complications
|
October 16, 2018
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease
Glenn M Chertow, Gerald B Appel, Geoffrey A Block, et al.
Page
of 48
Search research articles
Search
Showing results (421-430 of 478) with videos related to
Sort By:
Page
of 48
Clinical Journal of the American Society of Nephrology : CJASN
|
March 10, 2012
Eculizumab for dense deposit disease and C3 glomerulonephritis
Andrew S Bomback, Richard J Smith, Gaetano R Barile, et al.
The Journal of Clinical Investigation
|
December 5, 2002
NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele
Hiroyasu Tsukaguchi, Akulapalli Sudhakar, Tu Cam Le, et al.
Applied and Environmental Microbiology
|
December 22, 2009
High heterogeneity within methicillin-resistant Staphylococcus aureus ST398 isolates, defined by Cfr9I macrorestriction-pulsed-field gel electrophoresis profiles and spa and SCCmec types
M A Argudín, A Fetsch, B-A Tenhagen, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
July 26, 2011
Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy
Roberta Camilla, Hitoshi Suzuki, Valentina Daprà, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
July 20, 2023
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
Sean J Barbour, Fernando C Fervenza, Dilshani Induruwage, et al.
Kidney International
|
January 10, 2018
C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy
Andrew S Bomback, Dominick Santoriello, Rupali S Avasare, et al.
American Journal of Nephrology
|
December 20, 2003
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy
W Kline Bolton, Daniel C Cattran, Mark E Williams, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 14, 2018
<i>UBD</i> modifies <i>APOL1</i>-induced kidney disease risk
Jia-Yue Zhang, Minxian Wang, Lei Tian, et al.
BMC Nephrology
|
October 1, 2008
NPHS2 variation in focal and segmental glomerulosclerosis
Stephen J Tonna, Alexander Needham, Krishna Polu, et al.
Journal of Diabetes and Its Complications
|
October 16, 2018
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease
Glenn M Chertow, Gerald B Appel, Geoffrey A Block, et al.
Page
of 48